SRL
ADAP

Scientech Research LLC’s Adaptimmune Therapeutics ADAP Stock Holding History

Scientech Research LLC’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,205
Closed -$8.09K – 397
2023
Q4 		$8.09K Buy
+10,205
New +$5.75K 0.01% 309

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Scientech Research LLC's ADAP Position: Q1 2024 in Review

Scientech Research LLC sold out of Adaptimmune Therapeutics (ADAP) in Q1 2024, closing a stake of 10,205 shares — an estimated $8.09K sold.

Scientech Research LLC first reported a position in ADAP in Q4 2023 and held it in 1 quarter. The position peaked at $8.09K in Q4 2023. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2024.

  • Scientech Research LLC reported no remaining Adaptimmune Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Scientech Research LLC sold 10,205 Adaptimmune Therapeutics shares in Q1 2024, an estimated $8.09K.
  • Scientech Research LLC first reported a position in Adaptimmune Therapeutics in Q4 2023 and held it in 1 quarter.
  • Scientech Research LLC's Adaptimmune Therapeutics position peaked at $8.09K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2024.

Based on Scientech Research LLC's 13F filing for Q1 2024, filed 15 May 2024.